Cambridge Healthtech Institute ’s 2nd Annual

NASH and Fibrosis
( 非酒精性脂肪肝炎 (NASH) 和纤维症 )


Non-alcoholic Steatohepatitis (NASH) is a disease of the liver that starts with an accumulation of fat and proceeds to inflammation and scarring of the liver. The scarring begins as fibrosis, but can worsen to cirrhosis and eventual liver failure. The global incidence of NASH is rapidly rising and no medical treatments exist. Thus NASH drug development is a growing area of activity in the pharmaceutical industry. Despite the challenge of measuring NASH, there are a few NASH drug candidates in late-stage clinical trials and many more in Phase I and early Phase II trials. Liver fibrosis is similar to the fibrotic disease process in other organs, where scientific understanding and advances are also rapidly occurring. CHI's NASH and Fibrosis conference convenes discovery scientists in academics, biotech and pharma who work in the area of fibrosis, inflammation or liver disease to share insights, tools and stay abreast of this emerging and rapidly progressing field.

Who should attend: Discovery Biologists, Discovery Chemists, Medicinal Chemists, Pharmacologists, Preclinical Researchers, Translational Scientists from academics or industry in departments or areas of focus such as liver disease, immunology, metabolic diseases, inflammation, and fibrosis

Coverage will include, but is not limited to:

  • Overviews on Fatty Liver Disease progression and fibrosis
  • NASH clinical updates that include focus on cellular pathways/biology learnings
  • Lessons from recent preclinical results
  • New liver and lung fibrosis targets
  • Convergence of fibrosis, inflammation and mitochondrial dysfunction
  • Fibrosis translational tools: biomarkers and imaging
  • Fibrosis preclinical models: cellular and animal

* 活动内容有可能不事先告知作更动及调整。

Choose your language